Similarly, in the EXTREME trial of first-line use of platin/5-fluorouracil/cetuximab in relapsed or metastatic disease, outcomes were essentially identical for patients with less than or more than 40% EGFR-positive tumor cells (9). Here, EGFR is linked to neoplasm.